U.S. pulls COVID drug off the market as omicron sibling dominates cases - NJ.com
4/6/2022 12:00:00 AM3 yearsago
by The Associated Press
by The Associated Press
BA.2 accounts for 72% of the COVID-19 cases sequenced by health authorities.
GlaxoSmithKlines IV drug for COVID-19 should no longer be used because it is likely ineffective against the omicron subvariant that now accounts for most U.S. cases, federal health regulators said Tu… [+2282 chars]
full article...